Pancreatic Cancer Research

ResearcherTUM KlinikumActive in the last 2 years

Marina Lesina

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8427-3548; OpenAlex author ID A5072846406. Sources: OpenAlex.

Their work

Papers
20 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
103
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: 5 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 2 papers

Papers 20

  1. Pancreatic ductal adenocarcinoma: The Vision of Heracles. Co-author DOI 10.1016/j.ccell.2026.07.014↗
  2. Contrast enhanced CT and MRI interchangeably reflect tumor characteristics in murine pancreatic cancer. Co-author DOI 10.1038/s41598-026-56008-4↗
  3. A decision point between transdifferentiation and programmed cell death priming controls KRAS-dependent pancreatic cancer development. Co-author DOI 10.1038/s41467-025-56493-7↗
  4. c-Rel drives pancreatic cancer metastasis through fibronectin-integrin signaling-induced isolation stress resistance and EMT. Co-author DOI 10.1186/s12943-025-02486-5↗
  5. DOTA-Based Plectin-1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human Tissue. First author DOI 10.1002/anie.202318485↗
  6. Phenotype screens of murine pancreatic cancer identify a Tgf-α-Ccl2-paxillin axis driving human-like neural invasion. Co-author DOI 10.1172/jci166333↗
  7. Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2022.100815↗
  8. Deletion of pancreas-specific miR-216a reduces beta-cell mass and inhibits pancreatic cancer progression in mice. Co-author DOI 10.1016/j.xcrm.2021.100434↗
  9. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  10. Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1002/1878-0261.12699↗
  11. Combating pancreatic cancer during its Rip Van Winkle sleep. First author DOI 10.1038/s41422-020-0348-z↗
  12. Loss of Wasl improves pancreatic cancer outcome. Co-author DOI 10.1172/jci.insight.127275↗
  13. Subtypes of pancreatic stellate cells and distant metastasis of pancreatic ductal adenocarcinoma. First author DOI 10.21037/atm.2020.03.136↗
  14. The Role of Autophagy in Pancreatic Cancer: From Bench to the Dark Bedside. Co-author DOI 10.3390/cells9041063↗
  15. Early pancreatic cancer lesions suppress pain through CXCL12-mediated chemoattraction of Schwann cells. Co-author DOI 10.1073/pnas.1606909114↗
  16. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. Co-author DOI 10.1158/0008-5472.can-17-0634↗
  17. The immune network in pancreatic cancer development and progression. Co-author DOI 10.1038/onc.2013.257↗
  18. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death. Co-author DOI 10.1002/ijc.27916↗
  19. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Co-author DOI 10.1016/j.ccr.2011.03.009↗
  20. Early requirement of Rac1 in a mouse model of pancreatic cancer. Co-author DOI 10.1053/j.gastro.2011.04.043↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hana Algül · 17 shared papers, 2011–2026 · strength 1.98
  2. Kıvanç Görgülü · 7 shared papers, 2020–2026 · strength 0.99
  3. Roland Michael Schmid · 9 shared papers, 2011–2025 · strength 0.83
  4. İhsan Ekin Demir · 6 shared papers, 2017–2026 · strength 0.81
  5. Maximilian Reichert · 5 shared papers, 2013–2025 · strength 0.56
  6. Roland Rad · 4 shared papers, 2020–2026 · strength 0.56
  7. Guralp Onur Ceyhan · 4 shared papers, 2017–2026 · strength 0.45
  8. Dietrich Alexander Ruess · 4 shared papers, 2017–2025 · strength 0.41
  9. Irina Heid · 3 shared papers, 2011–2026 · strength 0.39
  10. Jiaoyu Ai · 3 shared papers, 2020–2025 · strength 0.38
  11. Carmen Mota Reyes · 3 shared papers, 2017–2026 · strength 0.37
  12. Bruno Sáinz · 3 shared papers, 2021–2025 · strength 0.36
  13. Rickmer Braren · 2 shared papers, 2021–2026 · strength 0.36
  14. Matthias M. Gaida · 2 shared papers, 2025–2026 · strength 0.35
  15. Dieter Saur · 3 shared papers, 2013–2026 · strength 0.35
  16. Katrin J. Frank · 2 shared papers, 2022–2025 · strength 0.28
  17. Fabian Karl Lohöfer · 1 shared paper, 2026 · strength 0.27
  18. Lea Würfel · 1 shared paper, 2026 · strength 0.27
  19. Sonia Alcalá · 2 shared papers, 2021–2025 · strength 0.25
  20. Helmut Friess · 2 shared papers, 2017–2026 · strength 0.25
  21. Henrik Einwächter · 2 shared papers, 2020–2025 · strength 0.25
  22. Katrin J. Ciecielski · 2 shared papers, 2020–2021 · strength 0.21
  23. Alexander Muckenhuber · 2 shared papers, 2021–2023 · strength 0.21
  24. Derya Kabacaoğlu · 2 shared papers, 2021–2022 · strength 0.20
  25. Pilhan Kim · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.